A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
A binary Xpovio catalyst is set for March.
Welireg, Padcev, and a surprise fillip for Flare.
AZD0120’s first pivotal trial will test settings as early as the second line.
Two new pivotal Chinese first-line trials have started in lung cancer.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
The company will start a phase 2/3 trial of PF-08634404 in March.
